Syfon offers a swallowable diagnostic capsule that collects stomach lining cells in a five‑minute, sedation‑free procedure, enabling gastric disease screening without endoscopy.
Funding
Funding not disclosed
Founders
Product
Problem
Gastric cancer and other gastrointestinal diseases often go undetected because screening requires invasive endoscopy, sedation, and specialist facilities, which are unavailable or unaffordable for the majority of the global population.
Solution
Syfon provides a swallowable diagnostic pill that collects gastric lining cells during a brief, five‑minute procedure without the need for sedation or endoscopy. The retrieved cells are analyzed using AI‑enhanced cytology and molecular assays to detect pre‑cancerous lesions, Helicobacter pylori infection, gastrointestinal bleeding, and other conditions. Results are generated quickly and can be interpreted by primary‑care clinicians, enabling point‑of‑care screening in clinics, community health programs, and remote settings. By offering an affordable, patient‑friendly test, Syfon expands early‑detection capabilities to underserved populations worldwide.
Target Audience
Primary customers are primary‑care physicians, community health clinics, and public‑health screening programs seeking accessible gastric disease diagnostics.
Features
- Swallowable capsule that safely harvests stomach lining cells in a minimally invasive, sedation‑free process
- AI‑driven cytological and molecular analysis pipeline for detection of pre‑cancer, H. pylori, bleeding, and additional GI pathologies
- Rapid turnaround of results suitable for point‑of‑care interpretation by non‑specialist clinicians
- Low per‑test cost designed for large‑scale deployment in primary‑care and community screening programs
- Compatibility with standard laboratory workflows for cytology and molecular testing